98%
921
2 minutes
20
Objective: Gene therapy by convection-enhanced delivery of type 2 adeno-associated virus-glial cell derived neurotrophic factor (AAV2-GDNF) to the bilateral putamina seeks to increase GDNF gene expression and treat Parkinson's disease (PD).
Methods: A 63-year-old man with advanced PD received AAV2-GDNF in a clinical trial. He died from pneumonia after anterior cervical discectomy and fusion 45 months later. An autopsy included brain examination for GDNF transgene expression. Putaminal catecholamine concentrations were compared to in vivo F-Fluorodopa (F-FDOPA) positron emission tomography (PET) scanning results before and 18 months after AAV2-GDNF infusion.
Results: Parkinsonian progression stabilized clinically. Postmortem neuropathology confirmed PD. Bilateral putaminal regions previously infused with AAV2-GDNF expressed the GDNF gene. Total putaminal dopamine was 1% of control, confirming the striatal dopaminergic deficiency suggested by baseline F-DOPA-PET scanning. Putaminal regions responded as expected to AAV2-GDNF.
Conclusion: After AAV2-GDNF infusion, infused putaminal regions showed increased GDNF gene expression, tyrosine hydroxylase immunoreactive sprouting, catechol levels, and F-FDOPA-PET signal, suggesting the regenerative potential of AAV2-GDNF in PD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341257 | PMC |
http://dx.doi.org/10.1002/mds.29820 | DOI Listing |
Toxicon
September 2025
Department of Pathology, College of Medicine, King Khalid University, P.O. 641, Abha, 61421, Saudi Arabia; Department of Forensic Medicine and Clinical Toxicology, Mansoura University, Egypt.
Titanium dioxide nanoparticles (TiO-NPs) are used in the production of various industrial and commercial products and reported to cause neurotoxicity in Sprague Dawley rats. Fortunellin (FRN) is a potent flavonoid with diverse biological properties. This research experiment was performed to explore the protective role FRN against TiO-NPs induced brain damage.
View Article and Find Full Text PDFCNS Neurosci Ther
September 2025
Center for Stem Cell & Gene Therapies Research & Practice, Kocaeli University, Kocaeli, Turkey.
Aims: Nanoparticle-mediated drug delivery systems are being investigated for the controlled release of drugs to treat neurodegenerative diseases (ND). We aimed to investigate the effects of poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs) containing different growth factors (GFs) on rat brain-derived neural stem cells (NSCs) in vitro differentiation, providing insights that may contribute to future approaches for treating Parkinson's disease.
Methods: Three different PLGA-NPs loaded with Brain-Derived Neurotrophic Factor (BDNF), Glial-Derived Neurotrophic Factor (GDNF), and Transforming Growth Factor beta 3 (TGF-β3) were developed and characterized in terms of size, zeta potential, encapsulation efficiency, and release profile.
Int J Ophthalmol
September 2025
Surakarta Central General Hospital, Surakarta 57144, Central Java, Indonesia.
Aim: To comprehensively investigate the current state of research on the application of neurotrophic factors in glaucoma therapy and identify potential research hotspots.
Methods: On September 30, 2023, a literature search was conducted on Scopus using specific keywords related to neurotrophic factors and glaucoma. Of the 918 articles retrieved, 780 met the inclusion criteria.
Sci Rep
August 2025
Department of Rehabilitation Medicine of Korean Medicine, Dongguk University, 814 Siksa-dong, Ilsandong-gu, Goyang-si, 10326, Republic of Korea.
Dyspepsia is a prevalent refractory condition that arises from various causes and lacks definitive treatment. There is an urgent need for evidence to support the use of herbal medicines in the treatment of gastroenterological disorders. This study aimed to compare the therapeutic effects of two common herbal formulas-namely, Shihosogan-tang (SST) and Yijung-tang (YJT)-on loperamide (LOP)-induced dyspepsia and to explore their potential mechanisms.
View Article and Find Full Text PDFCell Mol Life Sci
August 2025
Molecular Neurophysiology and Epilepsy Group, Epilepsy Center, Department of Clinical Sciences, Lund University Hospital, Epilepsy Center, Lund, 22184, Sweden.
Epilepsy is a central nervous system disorder causing uncontrollable seizures. One-third of patients do not respond to current medications, necessitating new treatments. This study targeted epileptogenesis, the process leading to chronic epilepsy, using human mesenchymal stem cells (MSCs) in a rodent model.
View Article and Find Full Text PDF